Introduction {#H1-1-ZOI200310}
============

Head and neck squamous cell carcinoma (HNSCC) is one of the leading causes of cancer death in the United States. There is an increasing incidence of human papillomavirus (HPV)-associated tumors with 53 000 new cases in 2019.^[@zoi200310r1],[@zoi200310r2]^ HPV-associated tumors more frequently have phosphoinositide 3-kinase (*PI3K*) gene variations independent of tobacco exposure.^[@zoi200310r3],[@zoi200310r4]^ By exploiting this oncogenic addiction phenotype, aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been identified as potential chemotherapeutic agents owing to the effect they have on cyclooxygenase inhibition, which is required for prostaglandin synthesis.^[@zoi200310r5]^ Concurrent use of NSAIDs has been shown to be associated with a survival advantage for colorectal cancer and a wide range of cancer histologies.^[@zoi200310r6]^

Whether NSAID use protects against the development of HNSCC remains controversial, as results have been mixed or inconclusive.^[@zoi200310r7],[@zoi200310r8],[@zoi200310r9],[@zoi200310r10],[@zoi200310r11]^ Recently, however, Hedberg et al found that regular NSAID use at any time improves disease-specific survival (DSS) and overall survival (OS) in patients with *PI3K*-altered HNSCC.^[@zoi200310r12]^ Less explored is the association of NSAID use with definitive chemoradiation therapy (CRT). This cohort study was performed using a large single institution HNSCC database to further examine the survival outcomes associated with NSAID use during CRT.

Methods {#H1-2-ZOI200310}
=======

The Roswell Park Comprehensive Cancer Center institutional review board approved this retrospective cohort study of patients with HNSCC diagnosed and treated at a single institution with CRT between January 1, 2005, and August 1, 2017. An approved waiver of consent was obtained from the Roswell Park Comprehensive Cancer Center because the research met the criteria for minimal risk to the study participants. This study did not follow the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.

Eligibility {#H2-1-ZOI200310}
-----------

To be included in this study, patients had to have the following criteria: (1) a first-time diagnosis of cancer, (2) an invasive squamous cell carcinoma limited to the head and neck, (3) treatment with CRT, and (4) successful completion of the treatment. Our complete patient selection criteria are shown in [Figure 1](#zoi200310f1){ref-type="fig"}. Overall, 781 patients with primary HNSCC were diagnosed or treated between January 1, 2005, and August 1, 2017. Of these, 460 (58.9%) met the selection criteria and had complete follow-up data.

![Patient Selection Criteria](jamanetwopen-3-e207199-g001){#zoi200310f1}

Data Collection, Treatment, and Follow-up {#H2-2-ZOI200310}
-----------------------------------------

Demographic and clinical characteristics of study participants, including age, sex, social habits, comorbidities (respiratory, cardiovascular, immune, renal, endocrine), and previous cancer history, were collected by a detailed medical chart review. No genetic testing was feasible, as most patients had very limited biopsy tissue. Patients were dichotomized by NSAID use during treatment, which was considered positive (NSAID+) if it was noted in the electronic medical record that the patient was taking NSAIDs regularly (at least daily) at the time of consultation and during treatment. Clinical information, such as stage, grade, HPV status, anatomical subsite, treatment modality, cancer recurrence, survival status, survival duration, and cause of death were also collected. Local control (LC) was defined as the absence of disease within the initial treatment volumes. Distant failure was defined as progression at a site or an organ that is noncontiguous with the initial site of disease, typically the lungs in the setting of head and neck cancer. The cisplatin-based chemotherapy (weekly or every 3 weeks) and intensity-modulated radiation therapy regimens (70 Gy to the primary tumor and 56 Gy to the elective lymph nodes in 35 fractions) applied in this cohort have been previously described in detail.^[@zoi200310r13],[@zoi200310r14]^ Patients could also be treated with induction chemotherapy, consisting of docetaxel, carboplatin, and fluorouracil, at the discretion of the medical oncologist.

Statistical Analysis {#H2-3-ZOI200310}
--------------------

Summary statistical analyses were performed from May 1, 2019, to March 17, 2020, and are provided for the demographic features of the patients included in this study. The associations of patient, tumor, and treatment characteristics with LC, DSS, and OS were examined using univariate analysis and multivariate Cox proportional hazard regression models. DSS is defined as death in a patient with a documented relapse, where patients are censored if there is death without known disease relapse. Analyses for the association between clinical outcomes and each particular variable were conducted. Only variables that were considered potential confounding factors were included before backward selection. All related factors that were significant at level α = .20 in the backward selection analyses were included in the final multivariate analysis. Survival estimates for OS and DSS were calculated using Kaplan-Meier survival curves. All tests were 2-sided, and *P* \< .05 was considered statistically significant. SAS, version 9.4 (SAS Institute, Inc) was used for statistical analyses.

Results {#H1-3-ZOI200310}
=======

A total of 460 patients (median \[interquartile range\] age, 60 \[53.9-65.6\] years; 377 \[82.0%\] men and 83 \[18.0%\] women) were included in the analysis. At the time of consultation and during treatment, 201 (43.7%) patients were taking NSAIDs. This therapy consisted of low-dose 81-mg aspirin once daily for 109 of 201 (53.7%) patients, high-dose 325-mg aspirin once daily for 22 (10.9%) patients, and other NSAIDs (ibuprofen, naproxen, or meloxicam) for the remaining 70 (34.8%) patients. Median follow-up was 4.0 years (interquartile range, 2.5-6.4 years). [Table 1](#zoi200310t1){ref-type="table"} includes patient, tumor, and treatment characteristics. To improve readability, an additional row for number of patients missing data under each variable was not included in [Table 1](#zoi200310t1){ref-type="table"} but can be imputed. The majority of the characteristics were well balanced; however, there was a higher proportion of patients with type 1 and type 2 diabetes and coronary artery disease in the NSAID+ group and a small increase of patients with larynx and hypopharynx primary tumor sites in the group not taking NSAIDs. Additionally, a greater proportion of patients in the group not taking NSAIDs were current smokers. In the univariate analysis, current smokers vs former or never smokers had significantly worse LC (hazard ratio \[HR\], 2.30; 95% CI, 1.31-4.06; *P* = .004) and OS (HR, 1.67; 95% CI, 1.23-2.28; *P* = .001) and no significant change in DSS (HR, 1.62; 95% CI, 0.95-2.76; *P* = .08). In the multivariate analysis, current smokers vs former or never smokers had worse LC (HR, 5.70; 95% CI, 2.02-20.55; *P* = .03), DSS (HR, 3.97; 95% CI, 2.01-8.01; *P* = .03), and OS (HR, 3.94; 95% CI, 2.00-8.00; *P* \< .001). Clinical tumor (T) stage was associated with worse LC in multivariate analysis (HR, 1.89; 95% CI, 1.42-2.52; *P* \< .001) and worse OS in univariate (HR, 1.45; 95% CI, 1.27-1.67; *P* \< .001) and multivariate (HR, 1.89; 95% CI, 1.42-2.52; *P* \< .001) analysis. Clinical nodal (N) stage was associated with worse OS in multivariate analysis (HR, 4.44; 95% CI, 2.19-9.30; *P* \< .001).

###### Baseline Patient, Tumor, and Treatment Characteristics[^a^](#zoi200310t1n1){ref-type="table-fn"}

  Variable                                                           No. (%) of patients   *P* value                                     
  ------------------------------------------------------------------ --------------------- ---------------------- ---------------------- ------
  Age, median (SD) \[range\]                                         60 (9.5) \[18-90\]    58.5 (9.6) \[33-90\]   61.0 (9.3) \[18-89\]   .45
  Sex                                                                                                                                    
  Male                                                               377 (82.0)            212 (81.9)             165 (82.1)             .98
  Female                                                             83 (18.0)             47 (18.1)              36 (17.9)              
  Comorbidities                                                                                                                          
  Respiratory disease                                                79 (17.2)             44 (17.0)              35 (17.4)              .92
  Diabetes mellitus                                                  57 (12.4)             21 (8.1)               36 (17.9)              .002
  Coronary artery disease                                            31 (6.7)              11 (4.2)               20 (10.0)              .02
  History of stroke or VTE                                           21 (4.6)              10 (3.9)               11 (5.5)               .47
  Alcohol consumption                                                                                                                    
  Never                                                              70 (15.2)             36 (13.9)              34 (16.9)              .46
  Former                                                             98 (21.3)             52 (20.1)              46 (22.9)              
  Current                                                            276 (60.0)            160 (61.8)             116 (57.7)             
  Not reported                                                       16 (3.5)              11 (4.2)               5 (2.5)                
  Smoking status                                                                                                                         
  Never                                                              103 (22.4)            61 (23.6)              42 (20.9)              .55
  Current                                                            115 (25.0)            75 (29.0)              40 (19.9)              .03
  Former                                                             242 (52.6)            123 (47.5)             119 (59.2)             .14
  T stage[^c^](#zoi200310t1n3){ref-type="table-fn"}                                                                                      
  T0                                                                 31 (6.8)              14 (5.5)               17 (8.5)               .37
  T1                                                                 55 (12.1)             36 (14.1)              19 (9.6)               
  T2                                                                 136 (29.9)            70 (27.3)              66 (33.2)              
  T3                                                                 161 (35.4)            94 (36.7)              67 (33.7)              
  T4a                                                                63 (13.9)             36 (14.1)              27 (13.6)              
  T4b                                                                9 (2.0)               6 (2.3)                3 (1.5)                
  N stage[^c^](#zoi200310t1n3){ref-type="table-fn"}                                                                                      
  N0                                                                 96 (30.0)             58 (22.6)              38 (18.9)              .71
  N1                                                                 52 (11.4)             28 (10.9)              24 (11.9)              
  N2a                                                                43 (9.4)              19 (7.4)               24 (11.9)              
  N2b                                                                132 (28.8)            75 (29.2)              57 (28.4)              
  N2c                                                                85 (18.6)             49 (19.1)              36 (17.9)              
  N3                                                                 50 (10.9)             28 (10.9)              22 (11.0)              
  Overall clinical stage[^c^](#zoi200310t1n3){ref-type="table-fn"}                                                                       
  0                                                                  1 (0.2)               0 (0.0)                1 (0.2)                .47
  I                                                                  2 (0.4)               1 (0.2)                1 (0.2)                
  II                                                                 23 (4.9)              12 (2.6)               11 (2.4)               
  III                                                                94 (20.7)             58 (12.8)              36 (7.9)               
  IVA                                                                287 (63.1)            156 (60.7)             131 (65.2)             
  IVB                                                                47 (10.3)             29 (11.3)              18 (4.0)               
  IVC                                                                1 (0.2)               1 (0.2)                0 (0)                  
  Primary tumor site                                                                                                                     
  Nasopharynx                                                        15 (3.3)              8 (3.1)                7 (3.5)                .02
  Oropharynx                                                         242 (52.6)            125 (48.3)             117 (58.2)             
  Oral cavity                                                        20 (4.3)              11 (4.2)               9 (4.5)                
  Larynx                                                             112 (24.3)            72 (27.8)              40 (19.9)              
  Hypopharynx                                                        40 (8.7)              30 (11.6)              10 (5.0)               
  Unknown primary                                                    31 (6.7)              13 (5.0)               18 (9.0)               
  HPV positive                                                                                                                           
  Yes                                                                179 (38.9)            95 (36.7)              84 (41.8)              .44
  No                                                                 94 (20.4)             52 (20.1)              42 (20.9)              
  Unknown                                                            187 (40.7)            112 (43.2)             75 (35.9)              
  Treatment                                                                                                                              
  Chemoradiation + neck dissection                                   26 (5.7)              14 (5.4)               12 (6.0)               .47
  ICT + chemoradiation                                               55 (12.0)             33 (12.7)              22 (10.9)              
  Chemoradiation                                                     379 (82.4)            212 (81.9)             167 (83.1)             

Abbreviations: HPV, human papillomavirus (p16 positive or HPV positive); ICT, induction chemotherapy; N, node; NSAID, nonsteroidal anti-inflammatory drug; T, tumor; VTE, venous thromboembolism.

To improve readability, an additional row for number of patients missing data under each variable was not included in [Table 1](#zoi200310t1){ref-type="table"} but can be imputed.

NSAID+ indicates that in the electronic medical record, the patient was noted to be taking NSAIDs regularly (at least daily) at the time of consultation and during treatment.

American Joint Committee on Cancer, 7th edition.

[Figures 2](#zoi200310f2){ref-type="fig"} and [3](#zoi200310f3){ref-type="fig"} show the Kaplan-Meier curves for OS and DSS, respectively. [Table 2](#zoi200310t2){ref-type="table"} shows univariate and multivariate analyses of LC, DSS, and OS for NSAID use. In the univariate analysis, NSAID use was not associated with improved LC (HR, 0.59; 95% CI, 0.31-1.10; *P* = .10) or DSS (HR, 0.82; 95% CI, 0.48-1.41; *P* = .47) but was significant for OS (HR, 0.63; 95% CI, 0.43-0.92; *P* = .02). In the multivariate analysis, after adjusting for concurrent anticoagulant use and cardiac history, clinical T and N stage, disease subsite, and smoking status, NSAID use remained significantly associated with better OS (HR, 0.59; 95% CI, 0.38-0.90; *P* = .02). NSAID use was not associated with better DSS after multivariate analysis (HR, 0.98; 95% CI, 0.57-1.70; *P* = .44). NSAID use was not associated with better response to treatment (HR, 1.44; 95% CI, 0.91-2.27; *P* = .12) or distant failure (HR, 1.12; 95% CI, 0.68-1.84; *P* = .65). After excluding nasopharyngeal cancer and unknown primary tumor, NSAID use was associated with improved OS in univariate (HR, 0.67; 95% CI, 0.49-0.92; *P* = .01) and multivariate (HR, 0.62; 95% CI, 0.40-0.97; *P* = .04) analysis. Alcohol consumption was not associated with DSS (HR, 1.04; 95% CI, 0.73-1.48; *P* = .84) or OS (HR, 1.15; 95% CI, 0.87-1.52; *P* = .32). In the multivariate analysis, former smokers had worse DSS (HR, 2.67; 95% CI, 1.06-6.80; *P* = .04) and worse OS (HR, 3.80; 95% CI, 2.0-7.21; *P* \< .001). Current smokers had no significant change in DSS (HR, 2.57; 95% CI, 0.91-7.24; *P* = .07) and significantly worse OS (HR, 4.02; 95% CI, 1.96-8.24; *P* \< .001). In multivariate analysis, cardiac history was significantly associated with DSS (HR, 2.56; 95% CI, 1.31-5.05; *P* = .006), but there was no significant association with worse OS (HR, 1.55; 95% CI, 0.98-2.46; *P* = .06). NSAID use was not associated with distant failure (HR, 1.15; 95% CI, 0.70-1.89; *P* = .59). Survival curves demonstrated a significantly better OS at 5 years for patients taking NSAIDs compared with those who were not (63.6% \[56 of 88 patients\]; 95% CI, 58%-73% vs 56.1% \[83 of 148 patients\]; 95% CI, 50%-63%; *P* = .03).

![OS for Patients Taking NSAIDs vs Patients Not Taking NSAIDs\
NSAID indicates nonsteroidal anti-inflammatory drug.](jamanetwopen-3-e207199-g002){#zoi200310f2}

![DSS for Patients Taking NSAIDs vs Patients Not Taking NSAIDs\
NSAID indicates nonsteroidal anti-inflammatory drug.](jamanetwopen-3-e207199-g003){#zoi200310f3}

###### UVA and MVA of NSAID Use vs No NSAID Use

  Variable                    UVA                MVA                      
  --------------------------- ------------------ ----- ------------------ -----
  Local control               0.59 (0.31-1.10)   .10   0.60 (0.31-1.12)   .11
  Disease-specific survival   0.82 (0.48-1.41)   .47   0.98 (0.57-1.70)   .44
  Overall survival            0.63 (0.43-0.92)   .02   0.59 (0.38-0.90)   .02

Abbreviations: HR, hazard ratio; MVA, multivariate Cox proportional hazard regression model; NSAID, nonsteroidal anti-inflammatory drug; UVA, univariate Cox proportional hazard regression model.

Discussion {#H1-4-ZOI200310}
==========

This large, retrospective cohort study suggests a significant association with improved OS for patients with HNSCC taking NSAIDs during definitive CRT. Contrary to prior analyses, there was no evidence that concurrent NSAID use was associated with reduced distant failure.^[@zoi200310r15],[@zoi200310r16]^ While the change in LC with NSAID use was not significant, future studies should continue to evaluate this possibility.

Few studies have previously examined the association between NSAID use during HNSCC treatment and patient survival. In a retrospective analysis examining 329 veterans, Lumley et al found that aspirin use after diagnosis and definitive treatment of HNSCC was associated with improved OS and DSS.^[@zoi200310r17]^ Although our results suggest improved OS with NSAID use, we did not find it to be associated with improved DSS. A similar Korean study evaluated 1392 patients with HNSCC and found that postdiagnosis treatment with NSAIDs was not significantly associated with recurrence, survival, or second-cancer occurrence.^[@zoi200310r18]^ This contrasts with our results, which could be related to the small sample size of patients taking NSAIDs or aspirin in their study (12.2%) compared with 43.7% in ours.

Hedberg et al reported specifically on patients with *PI3K*-altered HNSCC treated primarily with surgery and found a significant 5-year DSS and 5-year OS advantage for patients taking NSAIDs.^[@zoi200310r12]^ Although we were unable to test for *PI3K*, our results suggest an OS advantage but not a DSS advantage. Hedberg et al suggest that *PIK3CA* variations may be a clinically useful marker to identify which patients with HNSCC will benefit from NSAID use^[@zoi200310r12]^; however, until such testing is routine, the data presented here suggest that giving daily aspirin to patients with head and neck cancer who are receiving CRT may be associated with improved survival.

The exact mechanism by which NSAIDs are associated with survival in HNSCC remains unclear. Our study did not find a reduction in distant metastasis among patients taking NSAIDs, which is a potential explanation for the improved survival proposed by prior meta-analyses.^[@zoi200310r15],[@zoi200310r16]^ There was also no DSS advantage for patients taking NSAIDs observed in our study. This suggests the observed survival advantage may be associated with the cardiovascular benefits of NSAIDs rather than any chemoprotective properties they may have, particularly because there was a higher proportion of patients with diabetes and coronary artery disease in the group taking NSAIDs. This is increasingly important because the risk of noncancer death now surpasses that of cancer death, with heart disease being the leading cause of noncancer mortality.^[@zoi200310r19]^ The fact that anticoagulants were not associated with improved OS while NSAIDs were suggests that the cyclooxygenase mechanism may be a contributing factor to survival. This mechanism may be a combination of local recurrence reduction through cyclooxygenase inhibition and treatment of underlying cardiovascular disease.

Limitations {#H2-4-ZOI200310}
-----------

This study is limited by several factors. Because of the nature of a retrospective review, the results are prone to information bias from miscoding of patient data and medication entry errors. In regard to NSAIDs, we had access to patient comorbidity data but did not have the reason why patients were prescribed regular NSAID use; nor did we have the duration of use. The vast majority of patients noted to be taking NSAIDs at the time of consultation were taking a "baby" (81-mg) aspirin, which was continued during CRT. Another limitation is the imbalance of primary tumor sites between the cohorts, with a small increase of patients with larynx and hypopharynx primary tumor sites and current smokers in the group not taking NSAIDs. This is adjusted for using multivariate analysis and does not alter the significance of the results. Despite these limitations, this review provides a large cohort of patients treated for HNSCC with CRT and concurrently taking NSAIDS.

Conclusions {#H1-5-ZOI200310}
===========

The results of this study suggest that there may be an OS advantage for patients taking NSAIDs during chemoradiation for HNSCC. Further studies examining this association are warranted.
